Viewing Study NCT05896059


Ignite Creation Date: 2025-12-24 @ 2:32 PM
Ignite Modification Date: 2025-12-29 @ 8:57 PM
Study NCT ID: NCT05896059
Status: RECRUITING
Last Update Posted: 2023-06-09
First Post: 2023-05-24
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
Sponsor: Zhejiang Cancer Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module